Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

Jeanette Doorduijn; GW van Imhoff; Ronnie van der Holt; HC Schouten; MR Schaafsma; MA MacKenzie; JW Baars; MJ Kersten; Elly Lugtenburg; Martin van den Bent; RH Enting; Fokje Spoelstra; P Poortmans; Jacoline Bromberg

doi:10.1002/hon.2342

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

Jeanette Doorduijn, GW van Imhoff, Ronnie van der Holt, HC Schouten, MR Schaafsma, MA MacKenzie, JW Baars, MJ Kersten, Elly Lugtenburg, Martin van den Bent, RH Enting, Fokje Spoelstra, P Poortmans, Jacoline Bromberg

Research output: Contribution to journal › Article › Academic › peer-review

31 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	497-503
Number of pages	7
Journal	Hematological Oncology
Volume	35
Issue number	4
DOIs	https://doi.org/10.1002/hon.2342
Publication status	Published - 2017

Research programs

EMC OR-01

Access to Document

10.1002/hon.2342

http://hdl.handle.net/1765/96349

Cite this

Doorduijn, J., van Imhoff, GW., van der Holt, R., Schouten, HC., Schaafsma, MR., MacKenzie, MA., Baars, JW., Kersten, MJ., Lugtenburg, E., van den Bent, M., Enting, RH., Spoelstra, F., Poortmans, P., & Bromberg, J. (2017). Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. Hematological Oncology, 35(4), 497-503. https://doi.org/10.1002/hon.2342

@article{c2ad26dd332f44e8b62df291ee50806e,

title = "Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study",

author = "Jeanette Doorduijn and {van Imhoff}, GW and {van der Holt}, Ronnie and HC Schouten and MR Schaafsma and MA MacKenzie and JW Baars and MJ Kersten and Elly Lugtenburg and {van den Bent}, Martin and RH Enting and Fokje Spoelstra and P Poortmans and Jacoline Bromberg",

year = "2017",

doi = "10.1002/hon.2342",

language = "Undefined/Unknown",

volume = "35",

pages = "497--503",

journal = "Hematological Oncology",

issn = "0278-0232",

publisher = "John Wiley & Sons Ltd.",

number = "4",

}

Doorduijn, J, van Imhoff, GW, van der Holt, R, Schouten, HC, Schaafsma, MR, MacKenzie, MA, Baars, JW, Kersten, MJ, Lugtenburg, E, van den Bent, M, Enting, RH, Spoelstra, F, Poortmans, P & Bromberg, J 2017, 'Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study', Hematological Oncology, vol. 35, no. 4, pp. 497-503. https://doi.org/10.1002/hon.2342

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. / Doorduijn, Jeanette; van Imhoff, GW; van der Holt, Ronnie et al.
In: Hematological Oncology, Vol. 35, No. 4, 2017, p. 497-503.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

AU - Doorduijn, Jeanette

AU - van Imhoff, GW

AU - van der Holt, Ronnie

AU - Schouten, HC

AU - Schaafsma, MR

AU - MacKenzie, MA

AU - Baars, JW

AU - Kersten, MJ

AU - Lugtenburg, Elly

AU - van den Bent, Martin

AU - Enting, RH

AU - Spoelstra, Fokje

AU - Poortmans, P

AU - Bromberg, Jacoline

PY - 2017

Y1 - 2017

U2 - 10.1002/hon.2342

DO - 10.1002/hon.2342

M3 - Article

C2 - 27530779

SN - 0278-0232

VL - 35

SP - 497

EP - 503

JO - Hematological Oncology

JF - Hematological Oncology

IS - 4

ER -